12. Restructuring Costs (Notes)

3 Months Ended

Mar. 31, 2022

Restructuring and Related Activities Disclosure [Text Block]

RESTRUCTURING COSTS

In February 2021, we announced our strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacts our operations in EMEA and includes the elimination of certain positions, the consolidation of certain functions, and the relocation of certain manufacturing operations from EMEA to APAC. The restructuring plan is being implemented in phases and is expected to be substantially complete by the end of 2022. The liability of $42.5 million as of March 31, 2022 consisted of $41.9 million recorded in Accrued payroll and employee benefits, $0.2 million recorded in Other current liabilities and $0.4 million recorded in Other long-term liabilities in the condensed consolidated balance sheets. The amounts reflected in Selling, general and administrative expense and Research and development expense were $0.2 million and $(0.1) million in the condensed consolidated statements of income (loss) for the three months ended March 31, 2022, respectively. The adjustments to expense recorded were primarily due to outplacement and training costs incurred, changes in the estimates of employee termination benefits and employees resigning or transferring to different positions within the company. From February 2021 to March 31, 2022, total expenses were $64.5 million.

The following table summarizes the activity of our European reorganization restructuring reserves (in millions):


	Life Science		Clinical Diagnostics		Total
Balances as of December 31, 2021:	$	5.2	$	41.9	$	47.1

Adjustment to expense	—		0.1		0.1
Cash payments	(1.3)		(2.3)		(3.6)
Foreign currency translation gains	—		(1.1)		(1.1)
Balances as of March 31, 2022:	$	3.9	$	38.6	$	42.5